Moleculin reports Q1 2024 results; Annamycin shows 62% CRc in 1st/2nd line AML

Moleculin Biotech, Inc.

R&D expense $4.3M, G&A $2.4M; cash $16.8M sufficient into Q4 2024.
MB-106 interim data: CRc 62% (54% CR) in 1st/2nd line AML (N=13).
All lines CRc 45% across 20 subjects; median durability 4.9 months and climbing.
Milestones: complete MB-106 H1 2024; EOP2 meeting H1 2024; pivotal trial H1 2025.
Received EMA Orphan Drug Designation for Annamycin in AML; U.S. patents issued.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Moleculin Biotech, Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 13, 2024, Moleculin Biotech, Inc. issued an updated press release announcing its financial results for the quarter ended March 31, 2024 and recent operational highlights.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-016162

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.